Author: [email protected]

Release – MAIA Biotechnology Reports Strong Initial Efficacy Data in Third-Line Non-Small Cell Lung Cancer from Phase 2 THIO-101 Part C Expansion Trial

Posted on by [email protected]
Primary Logo

Research News and Market Data on MAIA

July 08, 2026 9:45am EDT Download as PDF

90.5% interim disease control rate (DCR) observed with combination therapy

Initial Part C efficacy observations align with previously reported THIO-101 clinical activity despite a more heavily pre-treated patient population

CHICAGO, July 08, 2026 (GLOBE NEWSWIRE) — MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced positive initial efficacy data from its Phase 2 THIO-101 clinical trial expansion, Part C, evaluating its lead candidate, ateganosine, a dual mechanism of action drug incorporating telomere targeting and immunogenicity, as a third-line (3L) therapy for patients with advanced non-small cell lung cancer (NSCLC). 

Initial data from the THIO-101 Part C 3L studies1 show a disease control rate (DCR) of 90.5% (19 out of 21 patients) in the efficacy evaluable population who had at least one tumor scan after starting treatment. Patients are treated with ateganosine followed by cemiplimab (Libtayo®) in cycles of 21 days. Current chemotherapy treatments deliver an approximate 25-35% disease control rate.2

“The initial efficacy data from the Part C studies are consistent with the encouraging efficacy signals we previously reported for Parts A and B of THIO-101, including an 88% disease control rate in third-line NSCLC patients. This measure of efficacy is close to triple the reported outcome for standard-of-care chemotherapy treatment,” said Vlad Vitoc, Founder and Chief Executive Officer of MAIA Biotechnology. “Importantly, patients enrolled in Part C of our trial represent a more heavily pre-treated population, with all patients having previously received docetaxel in addition to demonstrating resistance to both immunotherapy and other chemotherapies.”

MAIA recently announced that it has completed international enrollment in Part C of the Phase 2 THIO-101 expansion trial. Treatment with ateganosine followed by cemiplimab has shown an acceptable safety profile to date in a heavily pre-treated population.

About Ateganosine
Ateganosine (THIO, 6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2’-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment of ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.

About THIO-101 Phase 2 Clinical Trial
THIO-101 is a multicenter, open-label, dose finding Phase 2 clinical trial. It is the first trial designed to evaluate ateganosine’s anti-tumor activity when followed by PD-(L)1 inhibition. The trial is testing the hypothesis that low doses of ateganosine administered prior to cemiplimab (Libtayo®) will enhance and prolong immune response in patients with advanced NSCLC who previously did not respond or developed resistance and progressed after first-line treatment regimen containing another checkpoint inhibitor. The trial design has two primary objectives: (1) to evaluate the safety and tolerability of ateganosine administered as an anticancer compound and a priming immune activator (2) to assess the clinical efficacy of ateganosine using Overall Response Rate (ORR) as the primary clinical endpoint. The expansion of the study will assess overall response rates (ORR) in advanced NSCLC patients receiving third line (3L) therapy who were resistant to previous checkpoint inhibitor treatments (CPI) and chemotherapy. Treatment with ateganosine followed by cemiplimab (Libtayo®) has shown an acceptable safety profile to date in a heavily pre-treated population. For more information on this Phase II trial, please visit ClinicalTrials.gov using the identifier NCT05208944.

About MAIA Biotechnology, Inc.
MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.

Forward Looking Statements
MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, “MAIA,” “Company,” “we,” “our,” and “us” refers to MAIA Biotechnology, Inc. and its subsidiaries.

Investor Relations Contact
+1 (872) 270-3518
[email protected]

1 As of July 06, 2026
2 Matsumoto H, et al. Transl Lung Cancer Res 2021;10:2278–89

Primary Logo

Source: MAIA Biotechnology, Inc.

Released July 8, 2026

Release – Research Analyst Report on NanoViricides Rates Company “Outperform”; Separately, A “Fireside Chat” Interview of the Company’s President Dr. Anil Diwan Hosted by Mr. Dave Donlin was Published by StockInvestor Daily

Posted on by [email protected]
Research Analyst Report on NanoViricides Rates Company "Outperform"; Separately, A "Fireside Chat" Interview of the Company's President Dr. Anil Diwan Hosted by Mr. Dave Donlin was Published by StockInvestor Daily

Research News and Market Data on NNVC

Wednesday, 08 July 2026 08:30 AM

Topic: 

Company Update

SHELTON, CT / ACCESS Newswire / July 8, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), a clinical stage leader developing antiviral drugs that viruses cannot escape, reports that a Coverage Initiating Research Report on the Company by an Independent Analyst has been published, dated as of July 6, 2026.

The report rates the Company with a rating of “Outperform” and has assigned a target price of $6.00, based on the analyst’s estimates. This research report provides a summary of the Company’s current programs, as well as additional longer term programs. The report was written by Mr. Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc. The report and additional coverage of the Company is available at channelchek.com. The report is also available at the Company’s website, nanoviricides.com .

The Company provided publicly available information to the Analyst, and also provided answers to questions of a technical nature, as is typical. All estimates of timelines, financial projections and modeling, etc. were made independently by the Analyst. The Company does not provide guidance on its timelines or revenues, profit or loss projections, nor does it review or have any input into the independent assessments.

The Company has retained Noble Capital as part of its investor outreach program. No part of the Analyst’s compensation was, is, or will be directly or indirectly related to any specific recommendations or views expressed in the public appearance and/or research report. All views expressed in this report accurately reflect the Analyst’s personal views about the subject securities or issuers. This report is intended to provide general securities advice, and does not purport to make any recommendation that any securities transaction is appropriate for any recipient particular investment objectives, financial situation or particular needs.

In a separate update, NanoViricides reports that Anil R. Diwan, PhD, the Company’s President and Executive Chairman was interviewed in a “Fireside Chat” by host Mr. Dave Donlin. This video interview was published by StockInvestor Daily under the IPO-Edge program on June 29, 2026 and is available at https://ipo-edge.com/replay-fireside-chat-with-nanoviricides-president-exec-chairman-anil-r-diwan/. The video is also available on the Company’s website (nanoviricides.com). The video provides information on the Company’s technology, how it is differentiated from current approaches, and the current programs.

In this Fireside Chat, Dr. Diwan discussed:

  • How NanoViricides’ broad-spectrum antiviral drugs like its lead drug NV-387 work alongside vaccines.
  • NanoViricides advancing a broad-spectrum antiviral approach that will be effective even against variants with its lead drug NV-387; how this differs from current antivirals in treating viral diseases like RSV and FLU.
  • The company’s Orphan Drug Designation granted by the FDA and its filing for Rare Pediatric Disease Designation for Measles; how the Company benefits from these designations and the upcoming potential funding benefits.
  • The resurgence of Measles despite having a vaccine in place and how it has caused epidemics in Europe, Canada, Mexico, and Bangladesh, while also making headlines in the U.S. Why this is happening and what this return tell us about current protection against viral diseases that are thought to be eliminated by vaccines.
  • The resurgence of several viral infections globally, like Monkeypox and Ebola, and the WHO declaring global alerts as diseases come back with new virus variants for which there is no vaccine or treatment, and how NanoViricides can help.

ABOUT NANOVIRICIDES

NanoViricides, Inc. (the “Company”) (www.nanoviricides.com) is a clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company’s novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments.

The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company’s business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.

Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.

NV-CoV-2 (API NV-387) is our nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is our other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. The Company believes that since remdesivir is already US FDA approved, our drug candidate encapsulating remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.

The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides’ platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company’s pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.

This press release contains forward-looking statements that reflect the Company’s current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company’s expectations include, but are not limited to, those factors that are disclosed under the heading “Risk Factors” and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

The phrases “safety”, “effectiveness” and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA.

FDA refers to US Food and Drug Administration. IND application refers to “Investigational New Drug” application. cGMP refers to current Good Manufacturing Practices. CMC refers to “Chemistry, Manufacture, and Controls”. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency’s (EMA) committee responsible for human medicines. API stands for “Active Pharmaceutical Ingredient”. WHO is the World Health Organization. R&D refers to Research and Development.

Contact:
NanoViricides, Inc.
[email protected]

Public Relations Contact:
[email protected]

SOURCE: NanoViricides, Inc.

Release – Snail Games Launches ARK: Genesis Part 1 Ascended, ARK Tides of Fortune, and ARK: Dragontopia DLC; $11 Million from Deferred Revenue Backlog to be Recognized in Q3 2026

Posted on by [email protected]
Snail, Inc logo

Research News and Market Data on SNAL

July 7, 2026 at 8:30 AM EDT

PDF Version

CULVER CITY, Calif., July 07, 2026 (GLOBE NEWSWIRE) — Snail, Inc. (Nasdaq: SNAL) (“Snail Games” or the “Company”), a leading global independent developer and publisher of interactive digital entertainment, announced the official launch of ARK: Genesis Part 1 Ascended, ARK Tides of Fortune, and ARK: Dragontopia for ARK: Survival Ascended. In connection with the release of ARK: Genesis Part 1 Ascended, the Company expects to recognize approximately $11 million from its deferred revenue backlog in Q3 2026.

The launch of ARK: Genesis Part 1 Ascended marks the return of one of the franchise’s most ambitious DLCs and its iconic ocean biome to the Unreal Engine 5-powered survival experience. Available at no additional cost to ARK: Survival Ascended owners, Genesis Part 1 Ascended expands the game’s content offering with new environments, creatures, and survival challenges.

Launching alongside Genesis Part 1 Ascended is Tides of Fortune, a new premium expansion that transforms the simulated ocean of Genesis into a massive, map-wide nautical frontier. Within this new expansion, players can build fleets, engage in naval warfare, and explore the deepest reaches of ARK‘s oceanic ecosystem.

Additionally, Studio Wildcard shadow-dropped ARK: Dragontopia, an all-new premium expansion pass that introduces survivors to a vast aerial ecosystem where dragons rule the skies. Owners will receive included content updates on July 9 and in October, culminating in December with the release of a boundless skyworld map.

The launch of this trio of content (Genesis Ascended Part 1, Tides of Fortune, and Dragontopia) underscores Snail Games’ strategy of leveraging its established content portfolio to drive player engagement and expand the ARK ecosystem. As the Company continues to invest in franchise development, ARK remains a key pillar of Snail Games’ growth and portfolio.

For creators interested in collaborations, please contact [email protected].

About Snail, Inc.
Snail, Inc. (Nasdaq: SNAL) is a leading global independent developer and publisher of interactive digital entertainment for consumers around the world, with a premier portfolio of premium games designed for use on a variety of platforms, including consoles, PCs, and mobile devices. For more information, please visit: https://snail.com/.

Forward-Looking Statements:
This press release contains statements that constitute forward-looking statements. Many of the forward-looking statements contained in this press release can be identified by the use of forward-looking words such as “anticipate,” “believe,” “could,” “expect,” “should,” “plan,” “intend,” “may,” “predict,” “continue,” “estimate” and “potential,” or the negative of these terms or other similar expressions. These forward-looking statements include information about possible or assumed future results of Snail Games’ business, financial condition, results of operations, liquidity, plans and objectives. Forward-looking statements appear in a number of places in this press release and include, but are not limited to, statements regarding recognizing approximately $11 million from the Company’s deferred revenue backlog in Q3 2026 in connection with the release of ARK: Genesis Part 1 Ascended; the sustainable value of prior ARK content and the franchise’s strong long-term player ecosystem; Snail Games’ strategy of leveraging its established content portfolio to drive player engagement and expand the ARK ecosystem; ARK remaining a key pillar of Snail Games’ growth and portfolio as the Company continues to invest in franchise development; and assumptions underlying any of the foregoing. Further information on risks, uncertainties and other factors that could affect Snail Games’ financial results and business include Snail Games’ ability to strengthen its gaming portfolio’s visibility; Snail Games’ ability to expand and grow its franchise and increase its revenue; Snail Games’ ability to retain its key employees or maintain its Nasdaq listing; and the risks that are included in its filings with the Securities and Exchange Commission (the “SEC”) from time to time, including its annual reports on Form 10-K and quarterly reports on Form 10-Q filed, or to be filed, with the SEC. You should not rely on these forward-looking statements, as actual outcomes and results may differ materially from those expressed or implied in the forward-looking statements as a result of such risks and uncertainties. All forward-looking statements in this press release are based on management’s beliefs and assumptions and on information currently available to Snail Games, and Snail Games does not assume any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made.

Investor Contact:
John Yi and Steven Shinmachi
Gateway Group, Inc.
949-574-3860
[email protected]

Release – The Oncology Institute Completes Strategic Refinancing with OrbiMed, Repaying the Outstanding $86 Million Deerfield Convertible Note, Strengthening its Balance Sheet, and Improving Liquidity

Posted on by [email protected]
TOI Management LLC. Logo

Research News and Market Data on TOI

Jul 07, 2026

PDF Version

CERRITOS, Calif., July 07, 2026 (GLOBE NEWSWIRE) — The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, announced today that it has repaid its $86 Million senior secured convertible note with Deerfield Partners through a debt refinancing that includes new credit facilities from OrbiMed.

This transaction is intended to increase liquidity, improve operating flexibility and extend debt maturities. Under the new financing arrangements with OrbiMed, TOI repaid the outstanding balance of its $86 million senior secured convertible note with a new $75 million term loan with OrbiMed maturing in 2031 as well as approximately $11 million of cash from the balance sheet without raising additional equity. Daniel Virnich, MD, CEO of TOI, commented, “I’m extremely excited about our new financing relationship with OrbiMed to support this next phase of TOI’s growth and business model refinement. In addition to providing the company with improved liquidity and financial flexibility, this important transaction significantly extends debt maturities and establishes committed funding from two leading healthcare financing institutions.” Dr Virnich also commented, “We are very pleased that we were able to complete these transactions without diluting our important existing shareholders, and would like to thank Deerfield Healthcare for their many years of support to TOI as both a creditor and existing shareholder.”

“We are pleased to support TOI in its next phase of growth,” said Matthew Rizzo of OrbiMed. ” We are excited to play a role in TOI’s expansion and development as it continues to scale and drive long term value for its patients and contracted payors.”

About The Oncology Institute  (www.theoncologyinstitute.com):

Founded in 2007, The Oncology Institute, Inc. (NASDAQ: TOI) is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of approximately 2.0 million patients including clinical trials, transfusions, and other care delivery models traditionally associated with the most advanced care delivery organizations. With over 400 employed and network clinicians and over 100 clinics and network locations of care across five states and growing, TOI is changing oncology for the better. For more information visit www.theoncologyinstitute.com.

Forward Looking Statement

This communication contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or TOI’s future financial or operating performance and are often identified by words such as “believe,” “expect,” “anticipate,” “plan,” “intend,” “may,” “will,” “estimate,” “continue,” “project,” “target,” or similar expressions.

These forward-looking statements include, without limitation, statements regarding TOI’s growth strategy, liquidity, working capital needs, access to financing (including any asset-based credit facilities), expected operational and financial performance, and market opportunities. These statements are based on current expectations, assumptions, and information available to management and are not guarantees of future performance.

Actual results may differ materially from those expressed or implied in forward-looking statements due to a variety of risks and uncertainties, including, among others: changes in the healthcare regulatory environment; reimbursement and payor dynamics; competitive pressures; TOI’s ability to execute on its growth and value-based care strategy; access to capital and liquidity; and the impact of litigation, government investigations, or other proceedings.

Additional factors that could cause actual results to differ materially are described in TOI’s filings with the Securities and Exchange Commission, including the “Risk Factors” section of TOI’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q.

Forward-looking statements speak only as of the date made, and TOI undertakes no obligation to update or revise these statements to reflect events or circumstances occurring after the date of this communication, except as required by law.

Media
The Oncology Institute, Inc.
[email protected]

Investors
ICR Healthcare
[email protected]

Release – MariMed’s Nature’s Heritage Launches “The Nose Knows” Immersive, Science-Backed Consumer Education Campaign

Posted on by [email protected]
Primary Logo

Research News and Market Data on MRMD

July 07, 2026 7:00am EDTDownload as PDF

NORWOOD, Mass., July 07, 2026 (GLOBE NEWSWIRE) — MariMed’s (“MariMed”) (CSE: MRMD) (OTCQB: MRMD) award-winning flower, vape and concentrate brand, Nature’s Heritage™, today announced the launch of ‘The Nose Knows,’ an immersive, science-backed consumer education campaign designed to help consumers better understand which cannabis products and strains align best to their preferences. The campaign aims to educate consumers about the critical role aroma plays in delivering desired cannabis experiences and organizes cannabis strains into six categorizes to make purchase decisions easier and more effective.

Developed in collaboration with Dr. Riley Kirk, a PhD-trained pharmaceutical scientist specializing in cannabis and pharmacology, ‘The Nose Knows’ campaign was inspired by feedback from cannabis consumers surveyed across Massachusetts, Maryland, and Illinois. The survey found that a product’s THC potency percentage is the primary factor influencing purchases. According to Dr. Kirk, research indicates that consumers would achieve a more desirable and personalized experience by focusing instead on their natural attraction to certain scents when making their flower purchase.

“Our sense of smell is intimately tied to our brain’s processing centers for emotions and memory,” said Dr. Kirk. “We want to encourage people to follow their nose to find cannabis that fits their needs and allows for a more personalized and nuanced experience. Terpene labels are a great resource, but they can be confusing to consumers. Following your nose is simple and intuitive for everyone.”

‘The Nose Knows’ campaign features immersive in-store activations, sensory-driven displays, and large-scale murals highlighting six aroma-and-effect-driven categories: Jacks & Haze, Tropical & Citrus, Floral & Earthy, Desserts & Sweets, OG, Gas & Chem, and Exotics. Utilizing local artists to visually depict each intended experience, the campaign transforms participating retail spaces into educational environments that encourage consumers to smell flower and concentrates and use their nose to help discover products that are right for them. Consumers can also explore the campaign through Nature’s Heritage’s online “Find Your Flower” quiz. The quiz helps guide consumers toward products aligned with their preferences and desired effects.

“Today’s cannabis consumer overwhelmingly purchases products based on THC percentage. Cannabis is meant to be experienced through one’s senses, and the science supports the fact that focusing on aroma rather than potency will enhance a consumer’s cannabis experience,” said Tami Kirlis, Brand Director for Nature’s Heritage. “We developed ‘The Nose Knows’ campaign to educate consumers and shift their purchasing behaviors using their sense of smell.”

To learn more about Nature Heritage, including options for flower, RSO, concentrates and vapes, visit www.naturesheritagecannabis.com.

About MariMed
MariMed Inc. is a leading multi-state cannabis operator, known for developing and managing state-of-the-art cultivation, production, and retail facilities. Our award-winning portfolio of cannabis brands, including Betty’s Eddies™, Bubby’s Baked™, InHouse™, Nature’s Heritage™, and Vibations™, sets us apart as an industry leader. These trusted brands, crafted with quality and innovation, are recognized and loved by consumers across the country. With a commitment to excellence, MariMed continues to drive growth and set new standards in the cannabis industry. For additional information, visit www.marimedinc.com.

Media Contact:
Zach Galasso
DPA Communications 
Email: [email protected]
Phone: (978) 604-5423

Company Contact:
Howard Schacter
Chief Communications Officer 
Email: [email protected]
Phone: (781) 277-0007

Release – ISG to Announce Second-Quarter Financial Results

Posted on by [email protected]

Research News and Market Data on III

7/7/2026

STAMFORD, Conn.–(BUSINESS WIRE)– Information Services Group (ISG) (Nasdaq: III), a global AI-centered technology research and advisory firm, said today it will release its second-quarter financial results on Wednesday, August 5, 2026, at approximately 4:15 p.m., U.S. Eastern Time.

The firm will host a conference call with investors and industry analysts at 9 a.m., U.S. Eastern Time, the following day, Thursday, August 6. Dial-in details are as follows:

  • The dial-in number for U.S. participants is +1 (800) 715-9871.
  • International participants should call +1 (646) 307-1963.
  • The security code to access the call is 2802159.

Participants are requested to dial in at least five minutes before the scheduled start time.

A recording of the conference call will be accessible on ISG’s investor relations page for approximately four weeks following the call.

About ISG

ISG (Nasdaq: III) is a global AI-centered technology research and advisory firm. A trusted partner to more than 900 clients, including 75 of the world’s top 100 enterprises, ISG is a long-time leader in technology and business services that is now at the forefront of leveraging AI to help organizations achieve operational excellence and faster growth. The firm, founded in 2006, is known for its proprietary market data and research, in-depth knowledge and governance of provider ecosystems, and the expertise of its 1,500 professionals worldwide working together to help clients maximize the value of their technology investments.

Source: Information Services Group, Inc.

Release – CoreCivic Announces 2026 Second Quarter Earnings Release and Conference Call Dates

Posted on by [email protected]
CoreCivic

Research News and Market Data on CXW

July 7, 2026

PDF Version

BRENTWOOD, Tenn., July 07, 2026 (GLOBE NEWSWIRE) — CoreCivic, Inc. (NYSE: CXW) (“CoreCivic”) announced today that it will release its 2026 second quarter financial results after the market closes on Wednesday, August 5, 2026. A live broadcast of CoreCivic’s conference call will begin at 10:00 a.m. central time (11:00 a.m. eastern time) on Thursday, August 6, 2026.

To participate via telephone and join the call live, please register in advance. Upon registration at https://register-conf.media-server.com/register/BI99959d3b30da46f3a101e52cd0e2654d, telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number and a unique passcode.

Participants may access the audio-only webcast of the conference call from the Company’s website at www.corecivic.com under the “Events & Presentations” section of the “Investors” page. A replay of the webcast will be available for seven days.

About CoreCivic

CoreCivic is a diversified, government-solutions company with the scale and experience needed to solve tough government challenges in flexible, cost-effective ways. We provide a broad range of solutions to government partners that help build safer, healthier, and more productive communities one person at a time through residential corrections, detention, and reentry management, adjacent service offerings that include pharmaceutical, transportation, and alternatives to incarceration, and government real estate solutions. We are the nation’s largest owner of partnership correctional, detention and residential reentry facilities, and one of the largest operators of such facilities in the United States. We have been a flexible and dependable partner for government for more than 40 years. Our employees are driven by a deep sense of service, high standards of professionalism and a responsibility to help government better the public good. Learn more at www.corecivic.com.

Contact:Investors: Jeb Bachmann – Managing Director, Investor Relations – (615) 263-3024
 Media: Steve Owen – Vice President, Communications – (615) 263-3107

Release – Kelly Appoints Alan Stukalsky as Chief Product and Technology Officer

Posted on by [email protected]
Primary Logo

Research News and Market Data on Kelya

July 6, 2026

PDF Version

Industry veteran brings more than 25 years of technology and digital leadership to newly created role

TROY, Mich., July 06, 2026 (GLOBE NEWSWIRE) — Kelly (Nasdaq: KELYA, KELYB), a global workforce strategy and solutions provider, has appointed Alan Stukalsky as chief product and technology officer, effective July 13. Stukalsky joins the Kelly senior leadership team, reporting to CEO Chris Layden, and will be responsible for overseeing the company’s product strategy, technology capabilities, and digital innovation efforts across its portfolio of specialty businesses.

“The workforce solutions industry is at an inflection point. Companies who successfully embed AI into their operations to better serve clients and candidates are going to pull away from the field,” Layden said. “That work is already underway at Kelly. Alan will scale it, drive operational excellence across the enterprise, and accelerate the pace at which we’re launching products that will help clients build tech-enabled workforces. He’s done it before and we’re excited to see the impact he’ll bring.”

Stukalsky brings more than 25 years of technology leadership and digital transformation experience to the newly created role. Throughout his career, he has led large-scale modernization efforts, enterprise platform transformations, cloud migrations, AI-enabled innovation, and the development of new digital business models. He is widely recognized for aligning technology, product, and business strategy to create industry-leading talent solutions and deliver measurable outcomes for customers, employees, and shareholders.

Most recently, Stukalsky served as chief digital and information officer at LHH, part of the Adecco Group. Prior to LHH, Stukalsky spent more than 16 years at Randstad, holding dual executive roles as chief digital officer and chief information officer for North America.

“This is an exciting time to join Kelly. The company is investing in the technology and products that will define how it competes in an AI-driven market,” Stukalsky said. “I’m passionate about making it easier for clients and candidates to work with us, embedding AI into the fabric of how we operate, and ensuring the people we place are equipped with the tools they need to succeed. I look forward to partnering with the talented Kelly team to build on a strong foundation and accelerate growth.”

Stukalsky is a passionate advocate for inspiring future STEM professionals and active with Junior Achievement, Georgia State University’s CIS program, and STE(A)M Truck. He has served on numerous industry and community boards and has been recognized as Georgia CIO of the Year for Large Enterprises. He holds a Bachelor of Science in Mechanical Engineering from Georgia Tech and a Bachelor of Science in Mathematics from Emory University.

About Kelly®
Kelly Services, Inc. (Nasdaq: KELYA, KELYB) helps companies recruit and manage skilled workers and helps job seekers find great work. Since inventing the staffing industry in 1946, we have become experts in the many industries and local and global markets we serve. With a network of suppliers and partners around the world, we connect approximately 375,000 people with work every year. Our suite of outsourcing and consulting services and solutions ensures companies have the people they need, when and where they are needed most. Headquartered in Troy, Michigan, we empower businesses and individuals to access limitless opportunities in industries such as science, engineering, technology, education, manufacturing, retail, finance, and energy. Revenue in 2025 was $4.3 billion.

Media Contact
Christian Taske
248-561-8823
[email protected]

This press release was published by a CLEAR® Verified individual.

Primary Logo

Release – Xcel Brands Announces Licensing Agreement with KBL Group for OFF/DUTY by Coco Rocha

Posted on by [email protected]
Primary Logo

Research News and Market Data on XELB

PDF Version

NEW YORK, July 06, 2026 (GLOBE NEWSWIRE) — Xcel Brands, Inc. (NASDAQ: XELB), a leading media and consumer products company specializing in influencer-led brands through social commerce and livestream shopping, today announced a licensing agreement with KBL Group for OFF/DUTY by Coco Rocha, the elevated fashion and accessories brand created in collaboration with internationally recognized supermodel, entrepreneur, educator, and fashion icon Coco Rocha.

Under the agreement, KBL Group will serve as the production partner for OFF/DUTY by Coco Rocha’s ready to wear collections, leveraging their expertise in sourcing, product development, manufacturing, and supply chain management to bring the brand’s vision to life. The partnership will support the continued growth of OFF/DUTY by Coco Rocha as the brand expands its fashion offerings across multiple retail distribution channels.

OFF/DUTY by Coco Rocha was created to reflect the realities of modern life, offering elevated wardrobe essentials designed for women constantly on the move. Inspired by the pieces Coco has relied on throughout her two-decade career of fashion weeks, international travel, business meetings, and family life. The brand delivers stylish, versatile, and functional pieces that seamlessly transition from day to night.

“KBL Group brings exceptional expertise in product development and manufacturing, making them an ideal partner for OFF/DUTY by Coco Rocha,” said Robert W. D’Loren, Chairman and Chief Executive Officer of Xcel Brands. “As we continue to build the brand, having a best-in-class partner capable of executing Coco’s vision with the highest standards of quality and craftsmanship is critical. We are excited to work together to create collections that resonate with today’s modern consumer.”

David Guisinger, Chief Executive Officer of KBL Group, added, “We are proud to partner with XCEL Brands and OFF/DUTY by Coco Rocha to bring a modern approach to dressing that is both aspirational and accessible. Coco’s authentic point of view and deep understanding of how women dress today have created a powerful foundation for the brand. By combining XCEL’s innovative approach to brand building with KBL’s expertise in product development, sourcing and execution, we are creating a meaningful lifestyle brand that reflects today’s consumer, confident, versatile and effortlessly sophisticated, while developing growth opportunities across multiple channels of distribution.”

About Xcel Brands

Xcel Brands, Inc. (NASDAQ: XELB) is a media and consumer products company engaged in the design, licensing, marketing, live streaming, and social commerce sales of branded apparel, footwear, accessories, fine jewelry, home goods, pet products and other consumer products, and the acquisition of dynamic consumer lifestyle brands. Xcel was founded in 2011 with a vision to reimagine shopping, entertainment, and social media as social commerce. Xcel is an industry leader in developing influencer led brands and owns the Halston and C. Wonder brands, as well as the co-branded influencer led brands Tower Hill by Christie Brinkley, Trust. Respect. Love by Cesar Millan, GemmaMade by Gemma Stafford and OFF/DUTY by Coco Rocha brand and holds a long-term license agreement in Mesa Mia by Jenny Martinez. Xcel also owns and manages the Longaberger by Shannon Doherty brand through its controlling interest in Longaberger Licensing, LLC. Xcel is pioneering a modern consumer products sales strategy which includes the promotion and sale of products under its brands through interactive television, digital live-stream shopping, social commerce, brick-and-mortar retailers, and e-commerce channels to be everywhere its customers’ shop. The company’s previously owned and current brands have generated more than $5 billion in retail sales via livestreaming in interactive television and digital channels alone and has over 20,000 hours of content production time in live-stream and social commerce. The brand portfolio reaches more than 46 million social media followers with broadcast reaching 200 million households. Headquartered in New York City, Xcel Brands is led by an executive team with significant live streaming, production, merchandising, design, marketing, retailing, and licensing experience, and a proven track record of success in elevating branded consumer products companies. For more information, visit www.xcelbrands.com.

For further information please contact:

Xcel Brands
[email protected]

About KBL Group

KBL Group is a globally-focused fashion brand development and sourcing partner that supports retailers and designers at every stage of the product lifecycle.  With a legacy that traces back to 1985, KBL has evolved into a strategic extension of its clients’ teams, blending market insight, creative design and international supply chain execution into comprehensive brand solutions.  Today, KBL Group operates with an integrated presence in New York and Hong Kong, aligning it’s global expertise to help fashion and lifestyle brands navigate a competitive, rapidly-changing marketplace.

For further information please contact:

KBL Group
[email protected]

About Coco Rocha

Coco Rocha is an internationally recognized supermodel, entrepreneur, educator, author, mentor, and advocate. Often referred to as the “Queen of Pose,” she has spent more than two decades at the forefront of the fashion industry, appearing on hundreds of magazine covers, walking for the world’s leading luxury brands, and starring in major global advertising campaigns.

Beyond modeling, Rocha has built a successful business career spanning fashion, education, television, and digital media. She is the founder of Coco Rocha Model Camp, where she has mentored thousands of aspiring and professional models from around the world, and currently serves as mentor and host of Project Runway Canada. Known for combining creativity, entrepreneurship, and education, Rocha continues to shape the future of fashion while inspiring audiences through her work as a businesswoman, mentor, and mother.

Primary Logo

Release – NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: “A Quest to Outrun ALS”

Posted on by [email protected]

Research News and Market Data on NRSN

Featuring renowned ALS expert Prof. Jeremy Shefner, the discussion will address key unmet needs in ALS, trial endpoint design, and PrimeC’s path forward

CAMBRIDGE, Mass., July 6, 2026 /PRNewswire/ — NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) (“NeuroSense”), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced its participation in a key opinion leader (KOL) webinar hosted by Roth Capital Partners titled “A Quest to Outrun Amyotrophic Lateral Sclerosis (ALS).” The webinar will bring together leading experts to discuss the current treatment landscape for ALS, persistent unmet medical needs, and emerging therapeutic approaches with the potential to change the course of the disease.

The live webinar will take place on Wednesday, July 8, 2026, at 11:00 a.m. Eastern Time and will be hosted by Boobalan Pachaiyappan, Ph.D., Managing Director and Senior Research Analyst at Roth Capital Partners, who covers the biotechnology sector. The discussion will feature Professor Jeremy Shefner, M.D., Ph.D., Chair of Neurology at Barrow Neurological Institute and Co-Founder of the Northeast ALS Consortium (NEALS), together with Alon Ben-Noon, Chief Executive Officer of NeuroSense.

To join the conversation, register in advance here.

The webinar will explore the most pressing questions in ALS drug development today – from the persistent unmet needs that continue to challenge patients and clinicians, to the clinical trial endpoints that may better capture disease progression. The discussion will also examine how NeuroSense’s PrimeC is positioned – mechanistically and clinically – relative to the current standard of care, what the pivotal Phase 3 PARAGON study will aim to demonstrate on the path toward potential FDA accelerated approval, and PrimeC’s longer-term commercial opportunity within an evolving ALS treatment landscape.

About NeuroSense

NeuroSense Therapeutics is a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease. The Company’s lead product candidate, PrimeC, is a novel oral therapy designed to target multiple key biological pathways underlying disease progression, including neuroinflammation, oxidative stress and dysregulated iron metabolism.

NeuroSense has generated compelling clinical data from its Phase 2b PARADIGM study in ALS, demonstrating meaningful slowing of disease progression. The Company also reported significant biological activity across multiple biomarkers associated with ALS, including microRNAs, supporting PrimeC’s multi-target mechanism of action. Notably, long-term follow-up data indicated a meaningful survival benefit, representing a potentially important advancement in the treatment of ALS.

NeuroSense has received clearance from the U.S. Food and Drug Administration (FDA) to initiate a pivotal Phase 3 clinical trial (PARAGON) in ALS, which is expected to enroll approximately 300 participants, primarily in the United States.

For additional information, we invite you to visit our website and follow us on LinkedIn, YouTube and X. Information that may be important to investors may be routinely posted on our website and these social media channels.

About PrimeC

PrimeC, NeuroSense’s lead drug candidate, is a novel extended-release oral formulation composed of a unique fixed-dose combination of two FDA-approved drugs: ciprofloxacin and celecoxib. PrimeC is designed to synergistically target several key mechanisms of ALS and AD, that contribute to neuron degeneration, inflammation, iron accumulation and impaired ribonucleic acid (“RNA”) regulation to potentially inhibit the progression of ALS and AD.

About ALS

Amyotrophic lateral sclerosis (“ALS”) is an incurable neurodegenerative disease that causes complete paralysis and death within 2-5 years from diagnosis. Every year, more than 5,000 people are diagnosed with ALS in the U.S. alone, with an annual disease burden of $1 billion. The number of people living with ALS is expected to grow by 24% by 2040 in the U.S. and EU.

Forward-Looking Statements

This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on NeuroSense Therapeutics’ current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements, including statements regarding the planned event, development, regulatory progress and potential commercialization of PrimeC, are based on assumptions as to future events that may not prove to be accurate. The future events and trends may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward looking statements. These risks include the uncertainty regarding the benefits of outcomes and the timing of current and future clinical trials; timing for reporting data, including from the study of PrimeC in Alzheimer’s disease; that the study will not be successful; the ability of NeuroSense to remain listed on Nasdaq; and other risks and uncertainties set forth in NeuroSense’s filings with the Securities and Exchange Commission (SEC). You should not rely on these statements as representing our views in the future. More information about the risks and uncertainties affecting NeuroSense is contained under the heading “Risk Factors” in the Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 31, 2026 and NeuroSense’s subsequent filings with the SEC. Forward-looking statements contained in this announcement are made as of this date, and NeuroSense undertakes no duty to update such information except as required under applicable law.

Logo: https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg

SOURCE NeuroSense

For further information: Email: [email protected] | Tel: +972 (0)9 799 6183

Release – Kratos Expands Oklahoma City Manufacturing Facility to Accelerate Production of Valkyrie, Firejet and Other Jet Drone Systems

Posted on by [email protected]
Primary Logo

Research News and Market Data on KTOS

July 6, 2026

PDF Version

106,000 Square Foot Facility Expansion Reflects Increased Demand for Kratos Jet Drones and Kratos’ Continued Investment in Strengthening the United States Defense Industrial Base Through Scalable, Efficient Manufacturing Capacity Capable of Producing Affordable, Mission-Ready Systems at Quantity and at Speed

SAN DIEGO, July 06, 2026 (GLOBE NEWSWIRE) — Kratos Defense & Security Solutions, Inc. (Nasdaq: KTOS), a technology company in the defense, national security and global markets, today announced a major expansion of its Oklahoma City manufacturing campus with the addition of over 100,000 square feet of manufacturing and production space. The expansion supports increasing customer demand for the company’s family of high-performance, affordable jet-powered drone systems, including the Valkyrie collaborative combat aircraft, the Firejet/Mighty Hornet IV and others.

The facility expansion represents Kratos’ continued investment in strengthening the United States defense industrial base through scalable, efficient manufacturing capacity capable of producing affordable, mission-ready systems at quantity and at speed. Today, Kratos produces approximately 165 high-performance jet drones annually, and this expansion will enable the company to further increase production to meet growing demand from the U.S. Department of War and allied customers.

“The future fight demands the ability to rapidly produce affordable, high-performance systems at scale,” said Steve Fendley, President of Kratos Unmanned Systems Division. “This expansion in Oklahoma City reflects our long-term commitment to investing ahead of customer demand and building the industrial capacity needed to support the Department of War’s modernization priorities. As autonomous systems become increasingly central to the future force, manufacturing readiness and producing at scale will be just as important as technology readiness, maybe more.”

The expanded facility will provide additional manufacturing, assembly, integration and test capacity for multiple Kratos tactical jet aircraft programs.

Production will support Valkyrie, the affordable, runway-flexible collaborative combat aircraft selected by the U.S. Marine Corps as the foundation of its Collaborative Combat Aircraft (CCA) program of record. Designed to operate solo, in swarms, or alongside crewed aircraft while providing additional mass, reach and mission capability, Valkyrie represents a new generation of affordable autonomous airpower. The expanded facility will also manufacture the Mighty Hornet IV, which is expected to serve as a key tactical capability supporting Taiwan’s defense requirements, reflecting growing international demand for affordable, high-performance unmanned systems.

The expanded facility will also support increased production capacity for Kratos’ family of high-performance aerial target systems, including the Firejet. Kratos’ Firejet system supports realistic operational test, evaluation and weapons training across the U.S. military and allied nations, with demand for advanced target capabilities continuing to grow, including for the test and training of missile, radar, air defense, C-UAS and directed energy weapon systems, and their crews.

Kratos has consistently invested in manufacturing infrastructure, production technologies, and workforce development to ensure the company can deliver affordable systems at the pace and scale required by evolving national security needs. The Oklahoma City expansion is the latest in a series of investments focused on expanding domestic production capacity and strengthening the resilience of the U.S. defense industrial base.

About Kratos Defense & Security Solutions
Kratos Defense & Security Solutions, Inc. (NASDAQ: KTOS) is a technology, products, system and software company addressing the defense, national security, and commercial markets. Kratos makes true internally funded research, development, capital and other investments, to rapidly develop, produce and field solutions that address our customers’ mission critical needs and requirements. At Kratos, affordability is a technology, and we seek to utilize proven, leading-edge approaches and technology, not unproven bleeding edge approaches or technology, with Kratos’ approach designed to reduce cost, schedule and risk, enabling us to be first to market with cost effective solutions. We believe that Kratos is known as an innovative disruptive change agent in the industry, a company that is an expert in designing products and systems up front for successful rapid, large quantity, low-cost future manufacturing which is a value-add competitive differentiator for our large traditional prime system integrator partners and also to our government and commercial customers. Kratos intends to pursue program and contract opportunities as the prime or lead contractor when we believe that our probability of win (PWin) is high and any investment required by Kratos is within our capital resource comfort level. We intend to partner and team with a large, traditional system integrator when our assessment of PWin is greater or required investment is beyond Kratos’ comfort level. Kratos’ primary business areas include virtualized ground systems for satellites and space vehicles including software for command & control (C2) and telemetry, tracking and control (TT&C), jet powered unmanned aerial drone systems, hypersonic vehicles and rocket systems, propulsion systems for drones, missiles, loitering munitions, supersonic systems, space craft and launch systems, C5ISR and microwave electronic products for missile, radar, missile defense, space, satellite, counter UAS, directed energy, communication and other systems, and virtual & augmented reality training systems for the warfighter. For more information, visit www.KratosDefense.com and follow Kratos on LinkedIn and X.

Notice Regarding Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Kratos and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Kratos undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Kratos believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Kratos in general, see the risk disclosures in the Annual Report on Form 10-K of Kratos for the year ended December 28, 2025, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the SEC by Kratos.

Press Contact:
Claire Cantrell
[email protected]

Kratos Investor Information:
877-934-4687
[email protected]

Primary Logo

Release – CoreCivic Sells Two Detention Facilities\

Posted on by [email protected]
CoreCivic

Research News and Market Data on CXW

July 6, 2026

PDF Version

BRENTWOOD, Tenn., July 06, 2026 (GLOBE NEWSWIRE) — CoreCivic, Inc. (NYSE: CXW) (CoreCivic or the Company) announced today that on July 2nd, 2026, it completed the sale of its 2,560-bed California City Detention Facility in California City, California (the California City Facility) and its 1,994-bed Otay Mesa Detention Center in San Diego, California (the Otay Mesa Facility) to the United States of America and its assigns, by and through the Department of Homeland Security for an aggregate gross sales price of $1.5 billion, including $732.6 million for the California City Facility and $739.2 million for the Otay Mesa Facility. These two purpose-built facilities were specifically designed to care for individuals in a secure environment. After federal and state income taxes of approximately $0.4 billion and transaction expenses, the Company anticipates its net proceeds from the asset sales to be approximately $1.1 billion.

The Company expects to use a portion of the net proceeds from the asset sales to

  • Repay all or a portion of the outstanding indebtedness under the Company’s Bank Credit Facility, which currently has an outstanding balance of $270.0 million on the Revolving Credit Facility, $107.8 million on the Initial Term Loan, and $100.0 million on the Incremental Term Loan, and
  • Repay the remaining outstanding balance of $238.5 million of the Company’s 4.75% senior notes, which are scheduled to mature in October 2027 (the 4.75% Notes).

The Company expects to use the remaining net proceeds for general corporate purposes, which may include additional debt repayments and share repurchases of the Company’s common stock. The credit agreement governing the Company’s Bank Credit Facility (the Credit Agreement) and the indenture (the 2029 Notes Indenture) governing the Company’s outstanding 8.25% senior notes due 2029 (the 8.25% Notes) limit our ability to make certain restricted payments, including share repurchases. However, the Company is permitted to make unlimited restricted payments (i) under the Credit Agreement, to the extent the Company’s consolidated secured leverage ratio (as defined therein) calculated on a pro forma basis after giving effect to such restricted payment would be equal to or less than 1.50 to 1.00 and no default exists thereunder, and (ii) under the 2029 Notes Indenture, to the extent the Company’s consolidated total leverage ratio (as defined therein) calculated on a pro forma basis after giving effect to such restricted payment would be equal to or less than 2.00 to 1.00. 

The Company also expects to maintain balance sheet flexibility to pursue growth opportunities. These opportunities include, but are not limited to, potential acquisitions within the Company’s lines of business and those that provide complementary services provided such opportunities enhance the Company’s business, diversify the Company’s cash flows, and/or increase the services the Company offers to its customers, similar to the acquisition of Clinical Solutions Pharmacy completed on April 1, 2026.

The Company currently expects to continue to manage the California City Facility and the Otay Mesa Facility under the existing management contracts with Immigration & Customs Enforcement (ICE) related to each facility, although the terms of the management contracts may be modified to reflect the change in ownership. However, the Company can provide no assurance that it will continue to manage these facilities in the future, or that the terms of the existing management agreements will remain the same. As has always been the case, ICE has the ability to terminate the management contracts for non-appropriation of funds or for convenience. The management contract for the California City Facility expires in August 2027, and the management contract for the Otay Mesa Facility expires in December 2029 and contains a five-year extension option.

In addition to these asset sales, the Company has been in discussions with ICE about the potential acquisition of additional detention facilities from the Company. These discussions are in various stages, and the Company can provide no assurance that any additional sales will occur.

Patrick Swindle, CoreCivic’s President and Chief Executive Officer, commented, “We are pleased with the sales of these two mission-critical facilities for the Company’s government partner, which demonstrates the value of the Company’s underlying real estate portfolio, while reflecting our role as a long-term, flexible solutions provider to government. The sale of these facilities at what we believe is a fair valuation provides the Company with significant balance sheet flexibility and positions us well to grow the Company’s businesses and return value to its shareholders, while remaining a dependable partner for government.”

About CoreCivic

CoreCivic is a diversified, government-solutions company with the scale and experience needed to solve tough government challenges in flexible, cost-effective ways. CoreCivic provides a broad range of solutions to government partners that help build safer, healthier, and more productive communities one person at a time through residential corrections, detention, and reentry management, adjacent service offerings that include pharmaceutical, transportation, and alternatives to incarceration, and government real estate solutions. CoreCivic is the nation’s largest owner of partnership correctional, detention and residential reentry facilities, and one of the largest operators of such facilities in the United States. CoreCivic has been a flexible and dependable partner for government for more than 40 years. CoreCivic’s employees are driven by a deep sense of service, high standards of professionalism and a responsibility to help government better the public good. Learn more at www.corecivic.com.

Forward-Looking Statements

This press release contains statements as to our beliefs and expectations of the outcome of future events that are “forward-looking” statements as defined within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from the statements made. These include, but are not limited to, the risks and uncertainties associated with: (i) changes in government policy, legislation and regulations that affect utilization of the private sector for corrections, detention, and residential reentry services, in general, or our business, in particular, including, but not limited to, the continued utilization of our correctional and detention facilities by the federal government as a consequence of presidential executive orders, changes in how the federal government, including ICE, elects to use our detention capacity or otherwise procures alternative detention capacity, and the impact of any changes to immigration reform and sentencing laws (we do not, under longstanding policy, lobby for or against policies or legislation that would determine the basis for, or duration of, an individual’s incarceration or detention); (ii) our ability to obtain and maintain correctional, detention, and residential reentry facility management contracts because of reasons including, but not limited to, sufficient governmental appropriations, contract compliance, negative publicity and effects of inmate disturbances; (iii) changes in the privatization of the corrections and detention industry, the acceptance of our services, the timing of the opening of new facilities and the commencement of new management contracts (including the extent and pace at which new contracts are utilized), as well as our ability to utilize available beds; (iv) our ability to successfully activate idle facilities in a timely manner in order to meet the growth in demand for our facilities and services from the federal government that has occurred as a result of changes in policies and actions of the current presidential administration, and to realize projected returns resulting therefrom; (v) general economic and market conditions, including, but not limited to, the impact governmental budgets can have on our contract renewals and renegotiations, per diem rates, and occupancy; (vi) fluctuations in our operating results because of, among other things, changes in occupancy levels; competition; contract renegotiations or terminations; inflation and other increases in costs of operations, including a rise in labor costs; fluctuations in interest rates and risks of operations; (vii) government budget uncertainty, the impact of debt ceilings and government shutdowns, including partial shutdowns, and changing budget priorities; (viii) our ability to successfully identify and consummate future development and acquisition opportunities, integrate their operations, and realize projected returns resulting therefrom; (ix) the availability of debt and equity financing on terms that are favorable to us, or at all; and (x) the potential for additional sales and intended use of proceeds from the asset sales described in this press release. Other factors that could cause operating and financial results to differ are described in the filings we make from time to time with the Securities and Exchange Commission.

We take no responsibility for updating the information contained in this press release following the date hereof to reflect events or circumstances occurring after the date hereof or the occurrence of unanticipated events or for any changes or modifications made to this press release or the information contained herein by any third-parties, including, but not limited to, any wire or internet services, except as may be required by law.

This press release is neither an offer to sell nor a solicitation of an offer to buy any securities, including the 4.75% Notes or the 8.25% Notes, nor shall it constitute a notice of redemption under the indenture governing the 4.75% Notes or the 2029 Notes Indenture, nor shall there be any offer, solicitation or sale of the 4.75% Notes, the 8.25% Notes or any other securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful.

Contact: Investors: Jeb Bachmann – Managing Director, Investor Relations – (615) 263-3024
Financial Media: David Gutierrez, Dresner Corporate Services – (312) 780-7204

Release – FreightCar America, Inc. Announces Milestone Multi-Year Order for 1,900 Railcars; Second Quarter Orders for Approximately 3,000 Railcars Represent a Commercial Inflection Point

Posted on by [email protected]
FreightCar America

Research News and Market Data on RAIL

07/06/2026

New Multi-Year Railcar Order Extends Backlog Visibility and Supports Second Quarter Commercial Momentum, Reflecting Customer Confidence in FreightCar America’s Commercial, Engineering and Manufacturing Platform

CHICAGO, July 06, 2026 (GLOBE NEWSWIRE) — FreightCar America, Inc. (NASDAQ: RAIL) (“FreightCar America” or the “Company”), a leading North American manufacturer and supplier of freight railcars, railcar parts and components, today announced that it has entered into a new multi-year order for 1,900 railcars from a key customer, with deliveries scheduled through 2028. The Company also announced that second quarter orders totaled approximately 3,000 railcars, representing a commercial inflection point as demand for differentiated, agile manufacturing solutions continues to grow.

Highlights

  • Secured a new multi-year order for 1,900 railcars, with deliveries scheduled through 2028, expanding backlog visibility and reflecting customer confidence in the Company’s execution and manufacturing capabilities.
  • Second quarter orders totaled approximately 3,000 railcars, valued at approximately $300 million, with orders received across every core market segment, reflecting broad-based demand and product diversity.
  • Multiple first-time customer orders, together with meaningful repeat customer activity, underscore strength of commercial presence, product offering and manufacturing platform.

“Customers are increasingly choosing FreightCar America because we are delivering what the market needs in conditions where customers need us most. Anchored by our engineering capability, manufacturing agility and focus on quality, we continue to position ourselves to gain share and capture significant order momentum during the quarter,” commented Nick Randall, President and Chief Executive Officer of FreightCar America. “This new multi-year commitment for 1,900 railcars is a testament to that, marking a milestone for the Company and showcasing the confidence our customers put into our ability to execute over a sustained delivery horizon.”

Randall continued, “With approximately 3,000 railcars ordered in the quarter, we are seeing an inflection point in terms of commercial momentum across our differentiated product portfolio. These orders highlight the value customers place on our ability to move quickly, tailor solutions to their needs and support transportation capacity across the North American supply chain. We believe FreightCar America is well positioned as an execution-focused railcar manufacturer in a market where reliability, responsiveness and delivery performance matter more than ever.”

Certain orders referenced in this release are subject to customary documentation and completion of terms.

About FreightCar America

FreightCar America, headquartered in Chicago, Illinois, is a leading designer, producer and supplier of railroad freight cars, railcar parts and components. We also specialize in railcar repairs, complete railcar rebody services and railcar conversions that repurpose idled rail assets back into revenue service. Since 1901, our customers have trusted us to build quality railcars that are critical to economic growth and instrumental to the North American supply chain. To learn more about FreightCar America, visit www.freightcaramerica.com.

Forward-Looking Statements

This press release contains statements relating to our expected financial performance, financial condition, and/or future business prospects, events and/or plans that are “forward-looking statements” as defined under the Private Securities Litigation Reform Act of 1995. Forward-looking statements represent our estimates and assumptions only as of the date of this press release. Our actual results may differ materially from the results described in or anticipated by our forward-looking statements due to certain risks and uncertainties. These potential risks and uncertainties relate to, among other things, the cyclical nature of our business; adverse economic and market conditions, including inflation; material disruption in the movement of rail traffic for deliveries; fluctuating costs of raw materials, including steel and aluminum; delays in the delivery of raw materials; our ability to maintain relationships with our suppliers of railcar components; our reliance upon a small number of customers that represent a large percentage of our sales; the variable purchase patterns of our customers and the timing of completion, delivery and customer acceptance of orders; the highly competitive nature of our industry; potential unexpected changes in laws, rules, and regulatory requirements, including tariffs and trade barriers; and other competitive factors. We expressly disclaim any duty to provide updates to any forward-looking statements made in this press release, whether as a result of new information, future events or otherwise.

Investor Contact: [email protected]

Primary Logo

Source: FreightCar America, Inc.

View all news